SONNET BIOTHERAPEUTICS HOLDINGS, INC.
SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG): 3 pipeline candidates · 2 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.38 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for SONNET BIOTHERAPEUTICS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$5.1M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in SONNET BIOTHERAPEUTICS HOLDINGS, INC.'s pipeline?
SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SONNET BIOTHERAPEUTICS HOLDINGS, INC.'s lead drug candidate?
SONNET BIOTHERAPEUTICS HOLDINGS, INC.'s most advanced tracked candidate is son-080 (Phase 2) for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Who is the CEO of SONNET BIOTHERAPEUTICS HOLDINGS, INC.?
Raghu Rao is the chief executive officer of SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG).
Get the full picture on SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.